Smith & Nephew PLC (SNN) saw its stock soar 8.26% on Tuesday during the 24-hour trading session, outperforming the broader market.
The medical technology company's strong performance was driven by impressive results, particularly in its U.S. orthopedics business. Smith & Nephew's U.S. orthopedics division posted underlying growth of 6% in the fourth quarter, exceeding expectations and boosted by strength in its hips and knees products.
Analysts at RBC Capital Markets commended the company's results, noting that the reassuring strength in the U.S. orthopedics segment will be welcomed by investors. Smith & Nephew also provided a 2025 outlook in line with consensus expectations and anticipates headwinds in China to clear through the first quarter, consistent with previous guidance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.